Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

270.12 USD -0.16 (-0.06%)
Official Closing Price Updated: 6:37 PM EST, Jan 21, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Biogen, Inc.

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Biogen Loses Patent Case Over Its Best-Selling Drug
A judge has ruled in favor of Mylan's challenge to Tecfidera's patent protection. 
Tags Market News MYL BIIB
From Motley Fool
US STOCKS-S&P 500 closes nominally higher amid COVID-19 spikes, muted data
* Indexes: Dow dips 0.15%, S&P up 0.06%, Nasdaq up 0.33% (Updates with closing prices) 
Tags companyNews
From Reuters: Company News
US STOCKS-S&P 500 closes nominally higher amid COVID-19 spikes, muted data
The S&P 500 closed nominally higher on Thursday as investors weighed a resurgence in coronavirus infections and the possibility of a new round of shutdowns as well as data that suggested the U.S.... 
Tags companyNews
From Reuters: Company News
Why Biogen's Stock Is Trading Lower Today
Biogen Inc (NASDAQ: BIIB) shares are trading lower on Thursday following reports the company has lost a patent dispute against Mylan for ... 
Tags General Benzinga why it's moving
From Benzinga
Biogen and Moderna shares show how biotech ETFs may look similar but act differently
Big shares of a losing biotech stock didn’t stop a pair of four-star-rated ETFs from moving higher Thursday. They may sound similar, but hold distinct investments once you look under the hood. 
Tags Financial Services Biotechnology BIIB
From MarketWatch
US STOCKS-Wall Street oscillates amid COVID-19 spikes, muted data
* Indexes mixed: Dow dips 0.52%, S&P off 0.27%, Nasdaq flat (Updates to late afternoon, changes dateline, byline) 
Tags companyNews
From Reuters: Company News
US STOCKS-S&P 500 muted as virus cases rise, jobless claims weigh
* Indexes mixed: Dow dips 0.25%, S&P flat, Nasdaq up 0.17% (Updates to early afternoon) 
Tags companyNews
From Reuters: Company News
US STOCKS-S&P 500, Dow muted as virus cases rise, jobless claims weigh
* Indexes: Dow flat, S&P up 0.16%, Nasdaq rises 0.47% (Adds quote, details; updates prices) 
Tags companyNews
From Reuters: Company News
Biogen Reportedly Loses Patent Battle With Mylan — And Shares Plunge
Biogen stock plunged Thursday after a West Virginia judge reportedly invalidated a patent protecting its multiple sclerosis blockbuster drug, Tecfidera, against a Mylan knockoff. 
From Investor's Business Daily
Morning Market Stats in 5 Minutes
Movers Indices • S&P 500 ETF (NYSE:SPY) decreased 0.56% to $309.82. • Nasdaq ETF (NASDAQ:QQQ) fell 0.14% to ... 
Tags MSFT GLD AMSWA
From Benzinga
Biogen Targets Coronavirus, Alzheimer's — But Is Biogen Stock A Buy?
Biogen is joining the hunt for a coronavirus treatment with Vir Biotechnology. Further, the company is working on an Alzheimer's drug. So, is now the time to buy Biogen stock? 
From Investor's Business Daily
Better Buy: Gilead Sciences vs. Biogen
One of these pharmaceutical giants has the only reasonably effective treatment so far for COVID-19, while the other has high hopes for its Alzheimer's disease drug candidate. 
Tags BIIB Market News GILD
From Motley Fool
Here are the best and worst stocks during the first 100 days of the coronavirus pandemic
The information-technology and consumer-discretionary sectors were the top performers. 
Tags Transportation HWM MAR
From MarketWatch
Chart of the Day: Biogen (BIIB)
Tags NASDAQ:BIIB
From StockNews.com
Notable Tuesday Option Activity: BIIB, KR, HRB
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (BIIB), where a total volume of 6,360 contracts has been traded thus far... 
Tags Stocks
From Market News Video
Implied MOAT Analyst Target Price: $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics
Each company aims to use its genome editing platform to treat disease, but which has an edge? 
Tags BLUE Market News SGMO
From Motley Fool
IBB, VRTX, BIIB, ILMN: Large Outflows Detected at ETF
Symbols mentioned in this story: IBB, VRTX, BIIB, ILMN Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
BIIB Makes Notable Cross Below Critical Moving Average
In trading on Thursday, shares of Biogen Inc (BIIB) crossed below their 200 day moving average of $287.39, changing hands as low as $281.20 per share. Biogen Inc shares are currently trading down about... 
Tags Stocks
From Market News Video
Should You Sell Biogen Stock?
With the biotech facing two issues each that could result in major headwinds, a Bernstein analyst has downgraded its stock. 
Tags BIIB Market News MYL
From Motley Fool
Benzinga's Top Upgrades, Downgrades For June 9, 2020
Upgrades B of A Securities upgraded the stock forOccidental Petroleum Corp(NYSE: OXY) from Neutral to Buy. Occidental ... 
Tags Initiation TMUS XHR
From Benzinga
4 Analysts On Why The Rumored AstraZeneca-Gilead Deal Is Unlikely To Materialize
The weekend was abuzz with rumors of U.K. pharma giant AstraZeneca plc's (NYSE: AZN) reported interest in U.S.-based large-cap ... 
Tags RBC Capital Markets Brian Abrahams ALXN
From Benzinga
Noteworthy Monday Option Activity: NAT, ZGNX, BIIB
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Nordic American Tankers Ltd (NAT), where a total of 40,927 contracts have traded so far,... 
Tags Stocks
From Market News Video
Despite Recent Speed Bumps, Biogen's Stock Will Soon Grow Again
The hard crashes and sharp rallies of the last two years belie a formidable and growing company. 
Tags BIIB SGMO Market News
From Motley Fool
Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win
The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising. 
Tags GSK GILD NVAX
From Motley Fool
Got $3,000? Here Are 3 Great Biotech Stocks to Buy Right Now
One big biotech and two small biotechs especially stand out as attractive picks. 
Tags AXSM IONS VRTX
From Motley Fool
Better Buy: Biogen vs. Axsome Therapeutics
One biotech has been big long-time winner, the other is a promising up-and-comer with no revenue -- yet. But picking an investment is always a bet on the future. 
Tags BIIB Market News AXSM
From Motley Fool
Noteworthy ETF Outflows: IVE, IBM, FIS, BIIB
Symbols mentioned in this story: IVE, IBM, FIS, BIIB Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units''... 
Tags ETFs
From ETF Channel
Here are the ‘hot dogs’ that hedge funds have used to outperform this year
Hedge funds have relied on technology, internet, media and telecom companies and increasingly more health care companies to drive performance. 
Tags BA LOW DAL
From MarketWatch
Is Biogen Stock A Buy Following An Unexpected Alzheimer's Drug Delay?
Biogen is joining the hunt for a coronavirus treatment with Vir Biotechnology. Further, the company is still working on an Alzheimer's drug. So, is now the time to buy Biogen stock? 
From Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.